CYTOKINETICS INC
For the period ended May 27, 2026. Filed Apr 17, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 27, 2026 · Filed Apr 17, 2026
CYTK$53.69-3.3%Stored close · as of Nov 6, 2026
Contents
Pay versus Performance Table
| Year · Summary Compensation Table Total for PEO(1) · Compensation Actually Paid to PEO(2) · Average Summary Compensation Table Total for non-PEO NEOs(3) · Average Compensation Actually Paid to non-PEO NEOs(4) · Value Of Initial Fixed $100 Investment Based On: | ||||||||
|---|---|---|---|---|---|---|---|---|
| Total Shareholder Return(5) · Peer Group Total Shareholder Return(6) · Net Loss (thousands) · Company Selected Measure(7) | ||||||||
| 2025 | $11,881,456 | $15,830,283 | $4,527,934 | $4,353,571 | $306 | $120 | $784,955 | — |
| 2024 | $14,363,456 | $(1,680,754) | $4,555,402 | $574,072 | $443 | $114 | $589,526 | — |
| 2023 | $8,743,126 | $20,675,807 | $2,914,219 | $6,431,731 | $787 | $115 | $526,244 | — |
| 2022 | $8,543,066 | $8,688,372 | $2,325,696 | $1,321,707 | $432 | $111 | $388,955 | — |
| 2021 | $6,414,999 | $19,860,766 | $2,749,683 | $6,474,352 | $430 | $125 | $215,314 | — |
| (1) | The amounts reported in this column reflect the total compensation reported for Mr. Blum (our PEO) for each corresponding years in the “Total” column of the Executive Summary Compensation Table included in our Proxy Statement for each of 2025, 2024, 2023, 2022, and 2021, with year 2021 adjusted as disclosed in footnote 3 to the Executive Summary Compensation Table included in our proxy statement for our 2023 Annual Meeting of Stockholders. Mr. Blum was our PEO for the entirety of each of our 2025, 2024, 2023, 2022, and 2021 fiscal years. |
| (2) | The amounts reported in this column represent the amount of CAP to Mr. Blum, as computed in accordance with Item 402(v)(2)(iii) of Regulation S-K. The amounts do not reflect the actual amount of compensation earned by or paid to Mr. Blum during the applicable year. In accordance with the requirements of Item 402(v)(2)(iii) of Regulation S-K, the following adjustments were made to Mr. Blum’s total compensation for each year to determine the CAP: |
| Year | Reported Summary Compensation Table Total for PEO | Reported Value of Equity Awards(a) | Aggregate Equity Award Adjustments(b) | Compensation Actually Paid to PEO |
|---|---|---|---|---|
| 2025 | $11,881,456 | $(10,245,936) | $14,194,763 | $15,830,283 |
| (a) | Represents the reported value of equity awards as reported in the “Stock and Option Awards” column in the Executive Summary Compensation Table for the applicable year. |
|---|
| 52 | Cytokinetics, Inc. | 2026 Proxy Statement |
| (b) | The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant besides the difference in grant price and ending applicable year share price. The amounts deducted or added in calculating the equity award adjustments are as follows: |
|---|
| Year | Year End Fair Value of Equity Awards Granted in the Year | Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year | Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year | Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year | Aggregate Equity Awards Adjustment |
|---|---|---|---|---|---|---|
| 2025 | $12,697,753 | $1,790,282 | $954,740 | $379,008 | $(1,627,020) | $14,194,763 |
| (3) | The amounts in this column represent the average of the amounts reported for the Company’s named executive officers as a group (excluding the Company’s PEO, Mr. Blum) in the “Total” column of the Executive Summary Compensation Table included in our Proxy Statement for each of our 2025, 2024, 2023, 2022, and 2021 fiscal years, with year 2021 adjusted as disclosed in footnote 3 to the Executive Summary Compensation Table included in our proxy statement for our 2023 annual meeting of stockholders, the Company’s named executive officers whose average compensation amounts are included in this figure are Mr. Lee, Mr. Hessekiel, Dr. Malik, and Mr. Callos. For 2024, the Company’s named executive officers whose average compensation amounts are included in this figure are Mr. Lee, Mr. Jaw (former Chief Financial Officer), Dr. Malik, Mr. Callos and Mr. Pletcher (former Chief Legal Officer). For 2023, the Company’s named executive officers whose average compensation amounts are included in this figure are Mr. Jaw, Dr. Malik, Mr. Callos and Robert Wong (former Chief Accounting Officer). For 2022, the Company’s named executive officers whose average compensation amounts are included in this figure are Mr. Jaw, Dr. Malik, Mr. Callos, David W. Cragg (former Chief Administration Officer), Mark A. Schlossberg (former General Counsel and Secretary) and Mr. Wong. For 2021, the Company’s named executive officers whose average compensation amounts are included in this figure are Mr. Jaw, Dr. Malik, Mr. Callos and Mr. Schlossberg. |
| (4) | The amounts do not reflect the actual average amount of compensation earned by or paid to the Company’s named executive officers as a group during the applicable year. In accordance with the requirements of Item 402(v)(2)(iii) of Regulation S-K, the following adjustments were made to average total compensation for the Company’s named executive officers as a group (excluding the Company’s PEO, Mr. Blum) for each year to determine the average CAP, using the same methodology described above in footnote 2 above to the Pay versus Performance Table: |
| Year | Average Reported Summary Compensation Table Total for Non-PEO NEOs | Average Reported Value of Equity Awards(a) | Average Equity Award Adjustments(b) | Average Compensation Actually Paid to Non-PEO NEOs |
|---|---|---|---|---|
| 2025 | $4,527,934 | $(3,762,788) | $3,588,425 | $4,353,571 |
| (a) | Represents the reported average value of equity awards as reported in the “Stock and Option Awards” column in the Executive Summary Compensation Table for the applicable year. |
|---|
| (b) | The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant besides the difference in grant price and ending applicable year share price. The amounts deducted or added in calculating the equity award adjustments are as follows: |
|---|
| Year | Year End Fair Value of Equity Awards Granted in the Year | Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year | Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year | Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year | Aggregate Equity Awards Adjustment |
|---|---|---|---|---|---|---|
| 2025 | $4,252,941 | $458,050 | $215,512 | $25,976 | $(1,364,054) | $3,588,425 |
| (5) | Cumulative TSR is calculated by the difference between the Company’s share price at the end and the beginning of the measurement period by the Company’s share price at the beginning of the measurement period. “Measurement period” is defined as: for 2021, the one-year period from market close December 31, 2020 through December 31, 2021; for 2022, the two-year period from market close on December 31, 2020 through December 31, 2022; for 2023, the three-year period from market close December 31, 2020 through December 31, 2023; for 2024, the four-year period from market close December 31, 2020 through December 31, 2024; and for 2025, the five-year period from market close December 31, 2020 through December 31, 2025. |
| (6) | Represents the Nasdaq Biotechnology Index. |
| (7) | We do not have a Company Selected Financial Measure as described in Item 402(v)(2)(vi) of Regulation S-K to link CAP to our performance. |
| Cytokinetics, Inc. | 2026 Proxy Statement | 53 |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.